This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A Third Look: Discussing the recent data from the phase 2 IGNAZ clinical trial of Felzartamab in patients with IgAN
Ticker(s): BIIBWho's the expert?
Institution: Eastern Nephrology Associates
- General nephrologist in practice for about 11 years, initially in an acedmeic center and then now in private practice and is the medical director of an incenter and home dialysis unit.
- Treats GN patients (IGA, FSGS etc), works in large chronic kidney disease clinic, and treats 300 patietnes with anemia related to CKD, 15 patients with Pruritus related to CKD.
- familiar with the results from the INNO2VATE Global Phase 3 trial of Vadadustat and the Phase II clinical trial data for the use of Oral Korsuva phase 2 data
Interview GoalTo discuss the current treatment landscape and the potential of Felzartamab, a therapy being developed by Biogen for the treatment of IgAN.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
